Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 4/20 | 0.56 |
| ▸ | DRD4 | P21917 | 11/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5757533 | 1.00 | SLC2A1 (0.56) | SLC2A1DRD4CYP2C9CYP2C19DRD2 | |
| SCHEMBL5757529 | 1.00 | SLC2A1 (0.56) | SLC2A1DRD4CYP2C9CYP2C19DRD2 | |
| SCHEMBL5758574 | 0.89 | SLC2A1 (0.60) | SLC2A1DRD4CYP1A2CYP3A4MAPT | |
| SCHEMBL5759487 | 0.89 | SLC2A1 (0.60) | SLC2A1DRD4CYP1A2CYP3A4MAPT | |
| SCHEMBL5759496 | 0.89 | SLC2A1 (0.60) | SLC2A1DRD4CYP1A2CYP3A4MAPT | |
| SCHEMBL5757000 | 0.84 | SLC2A1 (0.58) | SLC2A1DRD4CYP1A2CYP3A4MAPT | |
| SCHEMBL5760228 | 0.84 | SLC2A1 (0.58) | SLC2A1DRD4CYP1A2CYP3A4MAPT | |
| SCHEMBL5760232 | 0.84 | SLC2A1 (0.58) | SLC2A1DRD4CYP1A2CYP3A4MAPT | |
| SCHEMBL5756826 | 0.79 | SLC2A1 (0.55) | SLC2A1DRD4DRD2 | |
| SCHEMBL5753735 | 0.79 | SLC2A1 (0.55) | SLC2A1DRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343765-B1 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERAZINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2006-11-22 | — | — | EP | claimed |
| EP-1343765-B1 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERAZINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-20040077656-A1 | Quinolines and nitrogenated derivatives thereof substituted in 4-position by a piperazine-containing moiety and their use as antibacterial agents | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077656-A1 | Quinolines and nitrogenated derivatives thereof substituted in 4-position by a piperazine-containing moiety and their use as antibacterial agents | NQO2, ASNS, QARS1 | SLC2A1 3955/4885DRD4 545/4885CYP2C9 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.